Without a license deal then a CR is on the cards having only $100 million including the expected $11 million R&D rebate .... but hey people should have known that LC wasn't presenting recently to the Venture Capitalists Conference for a free lunch - just sayin'
There is also a remote possibility that the data later in the year impresses people so much that the share price rises that much that there is an incentive to pay up for the options .... who knows ?
Bring on the 10:1 consolidation and get on with it - remember folks this is a speculative biotech and it could all flop on the back of poor trial data, which I don't expect so we should all hope for the best but be prepared for the worst ?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)